Assessment of chemical contamination by cancer drugs during use of the RIVA

Occupational exposure antineoplastic drugs cancer drugs compounding robot robotization

Journal

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372

Informations de publication

Date de publication:
26 Aug 2024
Historique:
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 26 8 2024
Statut: aheadofprint

Résumé

Many hospitals are now investing in robotic compounding system for the preparation of cytotoxic agents. The objective of the present study was to describe contamination by cytotoxics inside and outside the RIVA We applied a risk analysis to determine which locations inside and outside the compounding robot should be monitored. Samples were collected by swabbing with a wet swab (using 0.1 mL of sterile water) before the robots was cleaned. Ten cytotoxics compounded with the robot were screened for using LC-MS/MS. We determined the percentage contamination rates inside (CR Our risk analysis highlighted 10 locations inside the robot and 7 outside. Ten sampling campaigns (10 samples per campaign) were performed. The mean CR The frequency of contamination was lower for robotic compounding than for manual compounding in an isolator. However, robotic compounding tended to generated larger mean amounts of contaminant; this was related to incidents such as splashing when syringes were disposed of after the compounding. The implementation of corrective actions effectively reduced the CRs. Further longer-term studies are required to confirm these results.

Identifiants

pubmed: 39183571
doi: 10.1177/10781552241276530
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10781552241276530

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Myriam Bouchfaa (M)

Institut de Pharmacie, CHU Lille, Lille, France.
Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Michèle Vasseur (M)

Institut de Pharmacie, CHU Lille, Lille, France.
Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Justin Courtin (J)

Institut de Pharmacie, CHU Lille, Lille, France.

Marine Pinturaud (M)

Institut de Pharmacie, CHU Lille, Lille, France.
Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Nicolas Beauval (N)

Univ. Lille, ULR 4483-IMPECS-IMPact de l'Environnement Chimique sur la Santé humaine, Lille, France.
CHU Lille, Pôle Biologie-Pathologie-Génétique, Unité Fonctionnelle de Toxicologie, Lille, France.

Delphine Allorge (D)

Univ. Lille, ULR 4483-IMPECS-IMPact de l'Environnement Chimique sur la Santé humaine, Lille, France.
CHU Lille, Pôle Biologie-Pathologie-Génétique, Unité Fonctionnelle de Toxicologie, Lille, France.

Pascal Odou (P)

Institut de Pharmacie, CHU Lille, Lille, France.
Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Nicolas Simon (N)

Institut de Pharmacie, CHU Lille, Lille, France.
Univ. Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Classifications MeSH